Invega Sustenna

Invega Sustenna

paliperidone

Manufacturer:

Johnson & Johnson
Concise Prescribing Info
Contents
Paliperidone palmitate
Indications/Uses
Acute & maintenance treatment of schizophrenia in adults.
Dosage/Direction for Use
IM Adult Initially 150 mg on day 1 & 100 mg 1 wk later in the deltoid muscle, followed by subsequent mthly dose of 75 mg. May adjust dose w/ in the range of 25-150 mg based on individual patient tolerability &/or efficacy.
Contraindications
Hypersensitivity to paliperidone, risperidone.
Special Precautions
Do not administer intravascularly or SC; divided inj. Discontinue in patients who develop signs or symptoms of neuroleptic malignant syndrome; tardive dyskinesia; hypersensitivity reactions, severe neutropenia. Patients w/ history of cardiac arrhythmias, congenital long QT syndrome & in concomitant use w/ drugs known to prolong QT interval; known CV disease eg, heart failure, MI or myocardial ischaemia, conduction abnormalities, cerebrovascular disease, or conditions that predispose patient to hypotension eg, dehydration, hypovolemia, antihypertensive therapy; history of seizure or conditions that potentially lower the seizure threshold; history of clinically significant low WBC count or drug-induced leucopenia/neutropenia; hyperprolactinaemia. Monitor for symptoms of hyperglycemia & DM. Closely monitor wt. Venous thromboembolism; Parkinson's disease & dementia w/ lewy bodies; priapism. May disrupt body's ability to reduce core body temp. Antiemetic effect may mask the signs & symptoms of overdosage of certain drugs or of conditions eg, intestinal obstruction, Reye's syndrome & brain tumor. Intraoperative Floppy Iris Syndrome. Not to be used in patients who are in an acutely agitated or severely psychotic state. May impair ability to drive & use machines. Renal & hepatic impairment. Pregnancy. Do not breastfeed when receiving Invega Sustenna. Childn & adolescents <18 yr. Elderly w/ dementia.
Adverse Reactions
Upper resp tract infection, cystitis; agitation, insomnia, nightmare, anxiety, anorgasmia, blunted affect, confusional state, decreased libido; akathisia, dizziness, extrapyramidal disorder, headache, somnolence/sedation, parkinsonism, cerebrovascular disorder, abnormal coordination, depressed level of consciousness, diabetic coma, head titubation, loss of consciousness, neuroleptic malignant syndrome, unresponsive to stimuli; HTN, flushing, hypotension, ischemia; abdominal pain/discomfort, constipation, diarrhea, dry mouth, nausea, toothache, vomiting, cheilitis, fecaloma, intestinal obstruction; pain in extremity, musculoskeletal pain, increased blood creatinine phosphokinase, muscular weakness, abnormal posture, rhabdomyolyis; asthenia, fatigue, inj site pain/reaction, increased/decreased body temp, drug w/drawal syndrome; increased wt; anemia, increased eosinophil count, decreased haematocrit; anaphylactic reaction; urine glucose present, hyperprolactinemia; hyperinsulinemia; conjunctivitis, eye movement disorder, glaucoma, photophobia; tinnitus; dysphonia, hyperventilation, aspiration pneumonia; rales; drug erruption, seborrheic dermatitis, skin discoloration; breast discharge/discomfort/engorgement/enlargement, menstrual disorder, delayed menstruation.
Drug Interactions
Drugs known to prolong the QT interval. Combination w/ other centrally acting drugs & alcohol. May antagonize effect of levodopa & other dopamine agonists. Therapeutic agents that induce orthostatic hypotension. Co-administration w/ carbamazepine, risperidone or oral paliperidone.
MIMS Class
ATC Classification
N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.
Presentation/Packing
Form
Invega Sustenna susp for inj 75 mg
Packing/Price
1's (Rp1,880,495/boks)
Form
Invega Sustenna susp for inj 100 mg
Packing/Price
1's (Rp1,880,495/boks)
Form
Invega Sustenna susp for inj 150 mg
Packing/Price
1's (Rp1,880,495/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in